SXTP VS RMED Stock Comparison

Performance

SXTP
10/100

SXTP returned -82.63% in the last 12 months. Based on SPY's performance of 13.09%, its performance is below average giving it a score of 10 of 100.

RMED
10/100

RMED returned -95.79% in the last 12 months. Based on SPY's performance of -8.73%, its performance is below average giving it a score of 10 of 100.

Profit

SXTP
10/100

Out of the last 4 quarters, SXTP has had 0 profitable quarters and has increased their profits year over year on 0 of them.

RMED
10/100

Out of the last 20 quarters, RMED has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

SXTP
38/100

SXTP has had a lower than average amount of volatility over the last 12 months giving it a score of 37 of 100.

RMED
44/100

RMED has had a lower than average amount of volatility over the last 12 months giving it a score of 44 of 100.

Analyst Price Targets

SXTP

"Analyst Price Targets" not found for SXTP

RMED
75/100

4 analysts offer 12-month price targets for RMED. Together, they have an average target of 0, the most optimistic target put RMED at 0 within 12-months and the most pessimistic has RMED at 0. These analyst ratings are from our partners at Financial Modeling Prep and Alpha Vantage.

Technicals

SXTP

"Technicals" not found for SXTP

RMED
11/100

RMED receives a 10 of 100 based on 14 indicators. 1 are bullish, 12 are bearish.

Earnings

SXTP

"Earnings" not found for SXTP

RMED
10/100

RMED has missed earnings 12 times in the last 20 quarters.

All score calculations are broken down here to help you make more informed investing decisions

60 Degrees Pharmaceuticals, Inc. Common Stock Summary

Nasdaq / SXTP

Healthcare

Biotechnology

60 Degrees Pharmaceuticals, Inc. operates as a specialty pharmaceutical company that engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19; Tafenoquine for fungal lung infections, tick-borne diseases, candidiasis, and other infectious and non-infectious diseases; and Celgosivir for respiratory viruses and dengue. The company was founded in 2010 and is based in Washington, District of Columbia.

Ra Medical Systems, Inc Summary

Healthcare

Medical Devices

Ra Medical Systems, Inc., a medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular immune-mediated inflammatory diseases. It offers destruction of arteriosclerotic blockages by laser radiation ablation, a minimally invasive excimer laser and single-use catheter system that is used by physicians in the endovascular treatment of vascular blockages resulting from lower extremity vascular disease. The company sells its products primarily through distributors in the United States. Ra Medical Systems, Inc. was incorporated in 2002 and is headquartered in Carlsbad, California.

Power up your portfolio